CAMBRIDGE, UK / December 1, 2025 — AstraZeneca PLC (“AstraZeneca”) has announced that as of 30 November 2025, the company’s issued share capital comprises 1,550,725,869 ordinary shares of US$0.25 each. No shares are held in Treasury, meaning the total number of voting rights in the company is 1,550,725,869.

Shareholders may use this figure as the denominator to determine whether they are required to notify any interest in, or change to their interest in, AstraZeneca under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.

Matthew Bowden, Company Secretary, stated:

“This disclosure ensures transparency and provides shareholders with the necessary information to assess their voting rights in AstraZeneca.”

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and are used by millions of patients worldwide.

For more information, visit astrazeneca.com and follow @AstraZeneca on social media.

This announcement is made in accordance with the FCA Disclosure Guidance and Transparency Rules and is provided via RNS, the news service of the London Stock Exchange.